Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27
|ClinicalTrials.gov Identifier: NCT00968214|
Recruitment Status : Active, not recruiting
First Posted : August 28, 2009
Last Update Posted : August 8, 2017
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at tumor and blood samples from postmenopausal women with primary breast cancer enrolled on clinical trial CAN-NCIC-MA27.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Genetic: polymorphism analysis Other: laboratory biomarker analysis|
- To identify genetic variation, as measured by single nucleotide polymorphisms, that is associated with musculoskeletal adverse events in specimens from postmenopausal women with hormone receptor-positive primary breast cancer receiving adjuvant aromatase inhibitors and enrolled on clinical trial CAN-NCIC-MA27.
OUTLINE: This is a multicenter study.
DNA from tumor tissue and blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
|Study Type :||Observational|
|Estimated Enrollment :||364 participants|
|Official Title:||A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.|
|Study Start Date :||September 2008|
|Estimated Primary Completion Date :||January 2100|
DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
|Genetic: polymorphism analysis Other: laboratory biomarker analysis|
- Genetic variation associated with musculoskeletal adverse events [ Time Frame: Up to 2 years ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00968214
|Study Chair:||James Ingle, MD||Mayo Clinic|